A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer.
Liu B, Liu L, Ran J, Xie N, Li J, Xiao H, Yang X, Tian C, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Hu ZY, Ouyang Q.
Liu B, et al. Among authors: hu x, hu zy.
ESMO Open. 2023 Jun;8(3):101563. doi: 10.1016/j.esmoop.2023.101563. Epub 2023 Jun 6.
ESMO Open. 2023.
PMID: 37285718
Free PMC article.
Clinical Trial.